AN2 Therapeutics (ANTX) Current Assets (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Current Assets data on file, last reported at $87.5 million in Q1 2026.

• Current Assets for Q1 2026 came in at $87.5 million, up 25.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.5 million (up 25.78% YoY), and the FY2025 annual result was $59.9 million, down 30.52% from the prior year.
• Current Assets climbed to $87.5 million in Q1 2026 per ANTX's latest filing, from $59.9 million in the prior quarter.
• Over five years, Current Assets peaked at $126.4 million in Q3 2023 and troughed at $59.9 million in Q4 2025.
• A 5-year average of $95.5 million and a median of $98.2 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 64.08% in 2022, then plunged 40.2% in 2025.
• A 5-year view of Current Assets shows it stood at $98.6 million in 2022, then gained by 12.05% to $110.5 million in 2023, then dropped by 21.94% to $86.3 million in 2024, then plunged by 30.52% to $59.9 million in 2025, then soared by 45.97% to $87.5 million in 2026.
• Business Quant data shows ANTX's Current Assets at $87.5 million in Q1 2026, $59.9 million in Q4 2025, and $64.0 million in Q3 2025.